Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA218870 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Expression data from human PBMCs from breast cancer patients and controls
| PRJNA141779 | ENA
Project description:To investigate the lncRNAs expression profiling in CD4+ T cells of systemic lupus erythematosus (SLE) patients, we have employed “Agilent Human lncRNA 4*180K microarray” as a discovery platform to identify lncRNAs and mRNAs expression signatures in CD4+ T cells between SLE patients and normal controls. CD4+ T cells were isolated from peripheral blood mononuclear cells (PBMCs) of peripheral blood in SLE patients and normal controls, respectively.
2021-08-05 | GSE181500 | GEO
Project description:We established m6A modification profiles using MeRIP-seq in peripheral blood mononuclear cells (PBMCs) from systemic lupus erythematosus (SLE) patients and controls (HC), and investigated m6A-related lncRNAs in SLE for novel potential roles in SLE. Compared with controls, m6A level was lower in SLE patients,426 lncRNAs and 2,331 mRNAs were differentially expressed in SLE patients.
2023-01-31 | GSE173312 | GEO
Project description:To further explore the role of long non-coding RNAs in the systemic lupus erythematosus (SLE), we assessed the transcriptome of PBMCs from healthy controls and SLE patients using ncRNA sequencing analysis. The data were analyzed for differential expression with a nominal P<0.05. Our study aimed to discover novel biomarkers for SLE diagnosis and prognosis.
2023-03-08 | GSE226933 | GEO
Project description:Peripheral blood mononuclear cells were collected from SLE patients in an observational study performed at the University of Michigan Blood microarray expression data were used to confirm the presence of an Interferon signature and identify additional surrogate genes RNA from PBMCs of SLE patients and normal donor controls were obtained for one time point and were profiled on Affymetrix arrays
2015-03-31 | E-GEOD-50772 | biostudies-arrayexpress
Project description:In this study, we analyzed the transcriptomes of ~276k single PBMCs from 33 childhood SLE (cSLE) and 11 healthy matched donors (cHD). Our findings were validated in an independent cohort including 8 adult SLE (aSLE) patients and 6 matched controls (aHD; ~132k PBMCs).
2020-09-02 | GSE135779 | GEO
Project description:Expression data from human Wegener’s granulomatosis patients and normal controls in PBMCs and in PMNs
| PRJNA121281 | ENA
Project description:Aberrant gene expression analysis between peripheral blood mononuclear cells (PBMCs) samples from healthy controls (HC) and patients with systemic lupus erythmatosus (SLE) were identified using Affymetrix gene arrays
2020-01-29 | GSE144390 | GEO
Project description:PBMCs from patients with Sjögren's syndrome and healthy controls
| PRJNA209872 | ENA
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.
2014-12-02 | GSE63741 | GEO